Self-built Supercritical CO2 Anti-solvent Unit Design, Construction and Operation using Carbamazepine

被引:8
作者
Meng, Dan [2 ]
Falconer, James [1 ]
Krauel-Goellner, Karen [3 ]
Chen, John J. J. J. [2 ]
Farid, Mohammed [2 ]
Alany, Raid G. [1 ]
机构
[1] Univ Auckland, Sch Pharm, Drug Delivery Res Unit 2DRU, Auckland, New Zealand
[2] Univ Auckland, Fac Engn, Dept Chem & Mat Engn, Auckland, New Zealand
[3] Massey Univ Wellington, IFNHH, Wellington, New Zealand
关键词
anti-solvent; carbamazepine; in vitro dissolution; particle size reduction; polymorphism; solid-state; supercritical CO2;
D O I
10.1208/s12249-008-9130-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purpose of this study was to design and build a supercritical CO2 anti-solvent (SAS) unit and use it to produce microparticles of the class II drug carbamazepine. The operation conditions of the constructed unit affected the carbamazepine yield. Optimal conditions were: organic solution flow rate of 0.15 mL/min, CO2 flow rate of 7.5 mL/min, pressure of 4,200 psi, over 3,000 s and at 33 degrees C. The drug solid-state characteristics, morphology and size distribution were examined before and after processing using X-ray powder diffraction and differential scanning calorimetry, scanning electron microscopy and laser diffraction particle size analysis, respectively. The in vitro dissolution of the treated particles was investigated and compared to that of untreated particles. Results revealed a change in the crystalline structure of carbamazepine with different polymorphs co-existing under various operation conditions. Scanning electron micrographs showed a change in the crystalline habit from the prismatic into bundled whiskers, fibers and filaments. The volume weighted diameter was reduced from 209 to 29 mu m. Furthermore, the SAS CO2 process yielded particles with significantly improved in vitro dissolution. Further research is needed to optimize the operation conditions of the self-built unit to maximize the production yield and produce a uniform polymorphic form of carbamazepine.
引用
收藏
页码:944 / 952
页数:9
相关论文
共 33 条
[1]  
[Anonymous], 1996, MERCK INDEX ENCY CHE
[2]  
ATTWOOD D., 2002, PHARM SCI DOSAGE FOR, V2nd, DOI 10.1360/zd-2013-43-6-1064
[3]  
Badilla JCDF, 2000, J SUPERCRIT FLUID, V17, P13
[4]   Supercritical and near-critical CO2 in green chemical synthesis and processing [J].
Beckman, EJ .
JOURNAL OF SUPERCRITICAL FLUIDS, 2004, 28 (2-3) :121-191
[5]   Solubility and conversion of carbamazepine polymorphs in supercritical carbon dioxide [J].
Bettini, R ;
Bonassi, L ;
Castoro, V ;
Rossi, A ;
Zema, L ;
Gazzaniga, A ;
Giordano, F .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 13 (03) :281-286
[6]   On the selection of optimum thermodynamic conditions for the GAS process [J].
de la Fuente, JC ;
Shariati, A ;
Peters, CJ .
JOURNAL OF SUPERCRITICAL FLUIDS, 2004, 32 (1-3) :55-61
[7]   Crystallization of pure anhydrous polymorphs of carbamazepine by solution enhanced dispersion with supercritical fluids (SEDS™) [J].
Edwards, AD ;
Shekunov, BY ;
Kordikowski, A ;
Forbes, RT ;
York, P .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 90 (08) :1115-1124
[8]  
*FDA, 2007, WAIV IN VIV BIOAV BI
[9]   Opportunities for process intensification using reverse micelles in liquid and supercritical carbon dioxide [J].
Goetheer, ELV ;
Vorstman, MAG ;
Keurentjes, JTF .
CHEMICAL ENGINEERING SCIENCE, 1999, 54 (10) :1589-1596
[10]   Polymorphic properties of micronized carbamazepine produced by RESS [J].
Gosselin, PM ;
Thibert, R ;
Preda, M ;
McMullen, JN .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2003, 252 (1-2) :225-233